apixaban + edoxaban + rivaroxoban + warfarin

The entry **apixaban + edoxaban + rivaroxoban + warfarin** refers to a grouping of anticoagulant medications utilized within the **TARGET-Type 2** pilot randomized controlled trial (NCT05419583). Sponsored by the **University of Edinburgh**, this trial evaluates a complex intervention of targeted cardiology assessment and guideline-directed treatment versus standard care in patients with type 2 myocardial infarction. The grouping includes three direct oral anticoagulants (DOACs)—apixaban, edoxaban, and rivaroxaban—which are small molecule inhibitors of Factor Xa, and warfarin, a small molecule vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors. In the context of the trial, these agents represent the range of anticoagulant options that could be prescribed as part of guideline-directed therapy for underlying coronary disease or left ventricular impairment.

Brand names

Xarelto